

Study design and rationale of the pAtients pResenTing with cOngenital heaRt dIseAse Register (ARTORIA-R)

Sinning, Christoph; Zengin, Elvin; Diller, Gerhard-Paul; Onorati, Francesco; Castel, María-Angeles; Petit, Thibault; Chen, Yih-Sharng; Lo Rito, Mauro; Chiarello, Carmelina; Guillemain, Romain; ...

Source / Izvornik: **ESC Heart Failure, 2021, 8, 5542 - 5550**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.1002/ehf2.13574>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:524548>

Rights / Prava: [Attribution-NonCommercial 4.0 International](#)/[Imenovanje-Nekomercijalno 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-07-18**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine
Digital Repository](#)



Study design and rationale of the pAtients pResenTing with cOngenital heaRt dIseAsE Register (ARTORIA-R)

Christoph Sinning^{1,2*}, Elvin Zengin¹, Gerhard-Paul Diller³, Francesco Onorati⁴, María-Angeles Castel⁵, Thibault Petit⁶, Yih-Shang Chen⁷, Mauro Lo Rito⁸, Carmelina Chiarello⁸, Romain Guillemin⁹, Karine Nubret-Le Coniat¹⁰, Christina Magnussen^{1,2}, Dorit Knappe¹, Peter Moritz Becher^{1,2}, Benedikt Schrage^{1,2}, Jacqueline M. Smits¹¹, Andreas Metzner¹, Christoph Knosalla^{12,13,14}, Felix Schoenrath^{12,13}, Oliver Miera¹⁵, Mi-Young Cho¹⁶, Alexander Bernhardt^{2,17}, Jessica Weimann¹, Alina Goßling¹, Amedeo Terzi¹⁸, Antonio Amodeo¹⁹, Sara Alfieri¹⁹, Emanuela Angeli²⁰, Luca Ragni²¹, Carlo Pace Napoleone²², Gino Gerosa²³, Nicola Pradegan²³, Inez Rodrigus²⁴, Julia Dumfarth²⁵, Michel de Pauw²⁶, Katrien François²⁷, Olivier Van Caenegem^{28†}, Arnaut Ancion²⁹, Johan Van Cleemput³⁰, Davor Miličić³¹, Ajay Moza³², Peter Schenker³³, Josef Thul³⁴, Michael Steinmetz^{35,36}, Gregor Warnecke³⁷, Fabio Ius³⁸, Susanne Freyt³⁸, Murat Avsar³⁸, Tim Sandhaus³⁹, Assad Haneya⁴⁰, Sandra Eifert⁴¹, Diyar Saeed⁴¹, Michael Borger⁴¹, Henryk Welp⁴², László Ablonczy⁴³, Bastian Schmack⁴⁴, Arjang Ruhparwar⁴⁴, Shiho Naito¹⁷, Xiaoqin Hua¹⁷, Nina Fluschnik¹, Moritz Nies¹, Laura Keil¹, Juliana Senftinger¹, Djemail Ismaili¹, Shinwan Kany¹, Dora Csengeri¹, Massimo Cardillo⁴⁵, Alessandra Olivetti⁴⁵, Giuseppe Faggian⁴, Richard Dorent⁴⁶, Carine Jasseron⁴⁶, Alicia Pérez Blanco⁴⁷, José Manuel Sobrino Márquez⁴⁸, Raquel López-Vilella⁴⁹, Ana García-Álvarez⁵, María Luz Polo López⁵⁰, Alvaro Gonzalez Rocafort⁵⁰, Óscar González Fernández⁵¹, Raquel Prieto-Arevalo⁵², Eduardo Zatarain-Nicolás⁵², Katrien Blanchart⁵³, Aude Boignard⁵⁴, Pascal Battistella⁵⁵, Soulef Guendouz⁵⁶, Lucile Houyel⁵⁷, Marylou Para⁵⁸, Erwan Flecher⁵⁹, Arnaud Gay⁶⁰, Éric Épailly⁶¹, Camille Dambrin⁶², Kaitlyn Lam⁶³, Cally Ho Ka-lai⁶⁴, Yang Hyun Cho⁶⁵, Jin-Oh Choi⁶⁶, Jae-Joong Kim⁶⁷, Louise Coats^{6,68}, David Steven Crossland^{6,68}, Lisa Mumford⁶⁹, Samer Hakmi⁷⁰, Cumaraswamy Sivathasan⁷¹, Larissa Fabritz^{1,72,73}, Stephan Schubert⁷⁴, Jan Gummert⁷⁵, Michael Hübler^{2,76}, Peter Jacksch⁷⁷, Andreas Zuckermann⁷⁸, Günther Laufer⁷⁸, Helmut Baumgartner³, Alessandro Giamberti⁸, Hermann Reichenspurner^{2,17†} and Paulus Kirchhof^{1,2,72,*†}

¹Department of Cardiology, University Heart and Vascular Centre Hamburg, Hamburg, Germany; ²German Centre of Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany; ³Department of Cardiology III, University Hospital Münster, Münster, Germany; ⁴Divisione Ospedaliero Universitaria Cardiochirurgia Verona, Verona, Italy; ⁵Heart Failure and Heart Transplantation Unit, Cardiology Department, ICCV, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain; ⁶Adult Congenital and Pediatric Heart Unit, Freeman Hospital Newcastle Upon Tyne, Newcastle Upon Tyne, UK; ⁷Department of Cardiovascular Surgery, National Taiwan University Hospital, Taipei, Taiwan; ⁸Department of Congenital Cardiac Surgery, IRCCS Policlinico San Donato, San Donato Milanese, Italy; ⁹Chirurgie cardio vasculaire, Hôpital Européen Georges-Pompidou HEGP, Paris, France; ¹⁰Programme de transplantation et d'assistance cardiaque adulte et pédiatrique au CHU de Bordeaux, Haut Lévêque Hospital, Pessac, France; ¹¹Eurotransplant, Leiden, The Netherlands; ¹²Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany; ¹³German Centre of Cardiovascular Research DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany; ¹⁴Charité University Medicine Berlin, Corporate Member of Freie University Berlin, Humboldt-University Berlin, and Berlin Institute of Health, Berlin, Germany; ¹⁵Department of Congenital Heart Disease/Pediatric Cardiology, German Heart Center Berlin, Berlin, Germany; ¹⁶Department of Congenital Heart Surgery/Pediatric Heart Surgery German Heart Center Berlin/Berlin, Germany; ¹⁷Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany; ¹⁸ASST Papa Giovanni XXIII, Bergamo, Italy; ¹⁹Bambino Gesù Pediatric Hospital and Research Institute, Rome, Italy; ²⁰Pediatric Cardiac Surgery and Adult Congenital Heart Disease Program, Department of Cardio-Thoracic and Vascular Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ²¹Pediatric Cardiology and Adult Congenital Heart Disease Program, Department of Cardio-Thoracic and Vascular Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ²²A.O.U Città della Salute e della Scienza, Torino, Italy; ²³Cardiac Surgery Unit, Cardio-Thoraco-Vascular and Public Health Department, Padova University Hospital, University of Padova, Padova, Italy; ²⁴Department of Cardiac Surgery, Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium; ²⁵Department of Cardiac Surgery, University of Innsbruck, Innsbruck, Austria; ²⁶Department of Cardiology, Universitair Ziekenhuis Gent, Ghent, Belgium; ²⁷Department of Cardiovascular Surgery, Universitair Ziekenhuis Gent, Ghent, Belgium; ²⁸Division of Cardiovascular Intensive Care and Heart Transplantation, Cliniques Universitaires Saint-Luc, Brussels, Belgium; ²⁹Department of Cardiology, Centre Hospitalier Universitaire de Liège, Liège, Belgium; ³⁰Department of Cardiology, Universitair Ziekenhuis Leuven, Leuven, Belgium; ³¹Department of Cardiology, Medical Faculty University of Zagreb, Zagreb, Croatia; ³²Department of Cardiovascular Surgery, University Hospital Aachen, Aachen, Germany; ³³Department of Surgery, University Hospital Bochum, Bochum, Germany; ³⁴Department of Pediatric Cardiology, University Hospital Giessen/Marburg, Giessen, Germany; ³⁵Department of Pediatric Cardiology, University Hospital Göttingen, Göttingen, Germany; ³⁶German Center of Cardiovascular Research (DZHK), Partner Site Göttingen, Göttingen, Germany; ³⁷Department of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany; ³⁸Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; ³⁹Department of Cardiovascular Surgery, University Hospital Jena, Jena, Germany; ⁴⁰Department of Cardiovascular Surgery, University Hospital Schleswig-Holstein, Kiel, Germany; ⁴¹Department of Cardiovascular Surgery, Heart Center Leipzig, Leipzig, Germany; ⁴²Department of Cardiac Surgery, University Hospital Münster, Münster, Germany; ⁴³Gottsegen György Hungarian Institute of Cardiology, Budapest, Hungary; ⁴⁴Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany; ⁴⁵Centro Nazionale Trapianti, Rome, Italy; ⁴⁶Agence de la Biomédecine, Saint-Denis, Paris,

France; ⁴⁷Organización Nacional de Trasplantes, Madrid, Spain; ⁴⁸Heart Failure and Transplant Unit, Virgen del Rocío Hospital Sevilla, Sevilla, Spain; ⁴⁹Heart Failure and Transplantation Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain; ⁵⁰Cirugía Cardiovascular, Servicio de Cirugía Cardiovascular Infantil y de Cardiopatías Congénitas, Hospital Universitario La Paz, Madrid, Spain; ⁵¹Heart Failure and Transplant Unit, Cardiology Department, Hospital Universitario La Paz, Madrid, Spain; ⁵²Department of Cardiology, Gregorio Marañón University Hospital CIBER-CV, Madrid, Spain; ⁵³Service de Cardiologie, CHU de Caen Normandie, Caen, France; ⁵⁴Department of Cardiology and Cardiovascular Surgery, CHU Michallon, Grenoble, France; ⁵⁵Department of Cardiology, Montpellier University Hospital, Montpellier Cedex 5, France; ⁵⁶Département de Cardiologie, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France; ⁵⁷M3C-Necker Enfants malades, AP-HP, Université de Paris, Paris, France; ⁵⁸Department of Cardiovascular Surgery and Transplantation, Bichat Hospital, AP-HP, Paris, France; ⁵⁹Division of Thoracic and Cardiovascular Surgery, Rennes University Hospital, Rennes, France; ⁶⁰Thoracic and Cardiovascular Surgery Department, Rouen University Hospital, Rouen, France; ⁶¹Department of Cardiac Surgery, Strasbourg University Hospital, Strasbourg, France; ⁶²Service de Cardiologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; ⁶³Department of Cardiology, Fiona Stanley Hospital, Perth, Australia; ⁶⁴Department of Cardiothoracic Surgery, Queen Mary Hospital, Hong Kong, China; ⁶⁵Department of Thoracic and Cardiovascular Surgery, Sungkyunkwan University, Seoul, South Korea; ⁶⁶Division of Cardiology, Department of Medicine, Sungkyunkwan University, Seoul, South Korea; ⁶⁷Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; ⁶⁸Congenital Heart Disease Research Group, Population Health Sciences Institute Newcastle University, Newcastle upon Tyne, UK; ⁶⁹NHS Blood and Transplant, Bristol, UK; ⁷⁰Department of Cardiology & Critical Care Medicine, Asklepios Klinik St. Georg, Hamburg, Germany; ⁷¹Department of Cardiothoracic Surgery, Mount Elizabeth Medical Centre, Singapore, Singapore; ⁷²Institute of Cardiovascular Sciences and SWBH and UHB NHS Trusts, Birmingham, UK; ⁷³Department of Cardiology, University Hospital Birmingham, Birmingham, UK; ⁷⁴Center for Congenital Heart Disease/Pediatric Cardiology, Heart and Diabetes Center NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany; ⁷⁵Department for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany; ⁷⁶Department of Pediatric Cardiac Surgery, University Heart & Vascular Center Hamburg, Hamburg, Germany; ⁷⁷Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria; and ⁷⁸Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria

Abstract

Aim Due to improved therapy in childhood, many patients with congenital heart disease reach adulthood and are termed adults with congenital heart disease (ACHD). ACHD often develop heart failure (HF) as a consequence of initial palliative surgery or complex anatomy and subsequently require advanced HF therapy. ACHD are usually excluded from trials evaluating heart failure therapies, and in this context, more data about heart failure trajectories in ACHD are needed to guide the management of ACHD suffering from HF.

Methods and results The pAtients pResenTing with cOngenital hearT dIseAsE Register (ARTORIA-R) will collect data from ACHD evaluated or listed for heart or heart-combined organ transplantation from 16 countries in Europe and the Asia/Pacific region. We plan retrospective collection of data from 1989–2020 and will include patients prospectively. Additional organizations and hospitals in charge of transplantation of ACHD will be asked in the future to contribute data to the register. The primary outcome is the combined endpoint of delisting due to clinical worsening or death on the waiting list. The secondary outcome is delisting due to clinical improvement while on the waiting list. All-cause mortality following transplantation will also be assessed. The data will be entered into an electronic database with access to the investigators participating in the register. All variables of the register reflect key components important for listing of the patients or assessing current HF treatment.

Conclusion The ARTORIA-R will provide robust information on current management and outcomes of adults with congenital heart disease suffering from advanced heart failure.

Keywords Adults with congenital heart disease; Heart transplantation; Heart failure; Ventricular assist device; Arrhythmia; Lung transplantation

Received: 25 May 2021; Revised: 30 July 2021; Accepted: 4 August 2021

*Correspondence to: Christoph Sinning and Paulus Kirchhof, Department of Cardiology, University Heart & Vascular Center Hamburg, Martinistr. 52, 20246 Hamburg, Germany. Tel: 004915222817675; 004940741052438. Email: c.sinning@uke.de; p.kirchhof@uke.de

[†]These authors were equally senior authors of the manuscript.

[‡]Deceased.

Introduction

Advances in medical and surgical treatment continue to improve outcome of children with congenital heart disease.¹ Consequently, these children are surviving to adulthood, resulting in a growing population of adults with congenital heart disease (ACHD).² ACHD now account for about two thirds of all patients with congenital heart disease.³ ACHD often develop severe cardiovascular problems due to residual disease or due to complications developing in the surgically-operated heart^{4,5}: ACHD with complex cardiac anatomy have a 20–50% risk of developing heart failure

(HF) during their lifetime.¹ Heart failure is responsible for approximately 20% of mortality in ACHD, often during early adulthood.⁶ The relatively small number of ACHD and their unique anatomy exclude them from heart failure trials. Consequently, there is a shortage of data to inform the optimal management of ACHD with HF.^{7–9} As HF often develops at young age in otherwise relatively healthy patients, heart transplantation is one of the most established options to treat ACHD with advanced HF. Problems listing these patients are well recognized as ACHD are commonly regarded to be in the lowest risk category and when reaching conventional criteria for urgent transplantation are often delisted due to

clinical deterioration or die on the waiting list.¹⁰ An international registry comprising unselected ACHD waiting for cardiac transplantation could provide information on the current management and outcomes in ACHD with advanced heart failure.

Methods

Study design

The ARTORIA-R is an international, observational project collecting retrospective data from 16 countries in the time period 1989 to 2020 and will thereafter include data prospectively (*Figure 1*). These data include patient demographics at evaluation for listing, waiting list details, post-transplant data and basic donor data. Future data will be updated annually in July each year, and each institution willing to contribute anonymized data to the register is invited to participate. The study is registered at ClinicalTrials.gov (<https://www.clinicaltrials.gov/>) of the United States Library of Medicine with the identifier: NCT04848844.

The study has been reviewed, in individual countries, in line with national requirements for ethical approval and followed according to local protocols for data management. Inclusion and exclusion criteria are shown in *Figure 2*. The complete variable manual of the ARTORIA-R is available in the Supporting Information, *Data S3*.

Study population

ACHD are included in the register if

- they are listed as an adult transplant candidate (≥ 18 years) for heart-only or heart-combined with other organs;
- they have a congenital heart defect;
- data are available from the initial evaluation for listing or the first listing on the waiting list;
- data of patients with advanced HF evaluated for listing but being in a too poor condition to be listed are entered as well;
- transferred data are anonymized; and
- the institution/organization agrees to the data management and scientific cooperation plan (Supporting Information, *Data S1*).

ACHD are excluded if


- if they are listed for a second heart transplantation (retransplantation).

The registry aims to achieve detailed information regarding the underlying congenital heart defect and the previous treatment of the patient. With this information, different cohorts [systemic left ventricle, systemic right ventricle, single ventricle (either anatomic left or right ventricle)] can be interrogated. Data will be collected about

Figure 1 Countries currently participating in the ARTORIA-R.



Created with mapchart.net

Figure 2 Institutions and organizations contributing data to the register and the inclusion and exclusion criteria.

medical treatment, the haemodynamic evaluation of the patient, laboratory testing to assess additional organ function of the kidney or liver, and treatment in the intermediate care or intensive care unit. As it is of special relevance in ACHD, treatment of arrhythmia, antiarrhythmic medication, and the use of intracardiac defibrillator (ICD) or cardiac resynchronization therapy (CRT) will be evaluated. Where available, data at the time of listing regarding ejection fraction of the systemic ventricle obtained by echocardiography or cardiac magnetic resonance imaging will be collected.

Inherited cardiomyopathies such as hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, or non-compaction cardiomyopathy are increasingly recognized as causes of cardiovascular diseases in children and young adults.^{11,12} The disease-causing mutations mainly alter cardiomyocyte function, and thus, the clinical presentation and the reasons for heart transplantation differ from those of patients with complex congenital heart disease. Comparing patient characteristics and outcomes between patients with inherited cardiomyopathies requiring heart transplantation with those of patients with congenital heart disease will strengthen the planned analyses. Separate analyses of these patient groups and comparisons between groups are planned. In addition, these patients are sometimes listed in the category of ACHD and thus reflect real-world practice. Thus, patient data with these specific diseases will be

collected for comparison with the ACHD cohort but not included in the original register.

During the study, additional institutions and organizations will be asked to include their data as well. Although the initial data are retrospective, additional data into the register will be entered prospectively.

Study objectives

The primary objective is to describe outcomes of ACHD evaluated for or listed on the waiting list for heart-only transplantation and heart-combined organ transplantation. Factors influencing outcomes, for example, underlying heart defect and type of anatomical correction, and medical therapy while on the waiting list, haemodynamic data, cardiopulmonary performance, and laboratory tests will be included in the analysis. We plan to calculate an ARTORIA-R score to estimate risk of adverse outcomes, defined as delisting due to clinical worsening or death while on the waiting list. In addition to ACHD listed on the waiting list, patients evaluated for listing but deemed to be in a too poor status for listing are entered as well.

Secondary objectives are related to additional important treatment factors in ACHD with advanced HF. These include ICD, CRT and arrhythmic events, for example, treatment of ventricular tachycardia or atrial fibrillation, in ACHD on the

waiting list. Further studies will focus on the impact and use of ventricular assist device (VAD) in ACHD on the waiting list. Comparison of the same anatomic defect with and without VAD treatment is foreseen. An additional aspect is the treatment of patients with univentricular heart and palliative surgery leading to a Fontan circulation. An important secondary objective is to analyse the effect of HF medication on the outcome. A specific analysis will assess the outcome of ACHD with increased pulmonary hypertension (PAH) requiring the need of combined heart and lung transplantation. In this context, ACHD with shunt lesions which were uncorrected and presenting with irreversible Eisenmenger syndrome represent an advanced PAH disease, which will be as well investigated. As the registry progresses, more outcome studies will be formulated. A current overview of the planned studies is shown in *Figure 3*.

Statistical considerations

Summary statistics will be reported for continuous variables as medians (25th percentile and 75th percentile) and for binary variables as absolute counts (frequencies). Categorization of ACHD in cohorts based on the year of evaluation or entering transplantation list is planned to assess time-dependent effects on patient characteristics and

outcomes. A non-parametric Spearman test will be used to examine a potential trend over the time intervals. The null hypothesis of no trend in data will be tested for every group.

Cumulative incidence analyses will be estimated wherein heart transplantation is considered as competing risk of the primary composite endpoint death on waiting list or delisting within 5 and 10 years and will be calculated by the Aalen–Johansen estimator for the 5/10 year follow-up period. Additional endpoints will as well be evaluated with the secondary endpoint of delisting due to improvement or all-cause mortality following transplantation.

To evaluate predictors of 5-/10-year death/delisting, univariable and multivariable Cox regression models will be fitted. For the multivariable Cox regression model, variables with less clinical relevance and with missing values in >20% of the sample are not used in the models. The Cox regression models will then be weighted by the Fine and Gray estimator, which accounts for the competing risk (transplantation or death/delisting).¹³

For all regression models, change in continuous variables will be modelled as change per standard deviation to enable the comparability of variables. A two-sided *P*-value of <0.05 will be considered statistically significant. Statistical calculations will be fitted to the projects as planned and adapted if needed.

Figure 3 Currently planned study projects with the outlook of additional projects in the future.

Primary objectives:

Evaluation process/ waiting list outcomes of ACHD

Characterisation of ACHD regarding device and arrhythmia management

Secondary objectives:

Heart failure medication in ACHD

Calculation of a risk score to identify ACHD with the highest urgency for listing

Impact of use of ventricular assist devices and characterisation of patients with VAD treatment

Outcome of patients with Eisenmenger syndrome as most severe form of PAH in ACHD

Frailty assessment and outcome of ACHD evaluated or listed for heart or heart/combined organ transplantation

Clinical characteristics of cohorts of ACHD with univentricular physiology, systemic right ventricle or patients without surgical correction in childhood

Future projects are open for discussion and can be submitted in the future

Ethic committee approval and data management/security

The current concept of the register was approved by the ethic committee of the federal county Hamburg in Germany on 2 September 2020 (file reference WF163-20). The study has been reviewed, in individual countries, in line with national requirements for ethical approval and followed according to local protocols for data management. All data will be combined in anonymized fashion at the data custodian institution (University Heart & Vascular Center Hamburg, Hamburg, Germany). For data management, each patient will be submitted with listing identification number or with a unique identification code for the institution that contributes data of the patient to the data custodian institution. After transmitting the data to this data custodian institution, the patient receives a new identification number, and thus, even the institution providing the data cannot identify the patient according to this new identification code. The data are centrally stored on secure servers. Each organization or institution contributing data to the registry names a representative who stores the copy of the password secured database on a safe data storage (additional points are outlined in the Supporting Information, *Data S2*). The study complies with the current General Data Protection Regulation in Europe enacted on 23 May 2018.

Discussion

Rationale

Treatment of ACHD with advanced HF is still uncommon, and these patients should be referred to specialized centres as these patients often need to be evaluated and listed for heart or heart and combined organs transplantation, most commonly the lung.^{1,14,15} In general, HF is more frequent in those with more complex heart defects: 22% of adults with transposition of the great arteries following an atrial switch (Senning or Mustard operation), 32% of adults with congenitally corrected transposition of the great arteries, and 40% of adults following Fontan completion. Given the increasing complexity and numbers of ACHD, advanced HF will be common in the future, and more patients will need evaluation for heart or heart and combined organ transplantation globally.¹⁶

What is currently known regarding heart transplantation in ACHD?

Previous reports could show that heart transplantation or even heart and lung transplantation is an effective treatment

for ACHD^{10,14,17,18}; however, a commonly encountered problem in listing ACHD is the issue of urgency as these patients often have a low priority while on the waiting list.^{10,14} On the other hand, multiple organ involvement with renal dysfunction, liver failure, complex anatomy, and pulmonary arterial hypertension (PAH) contributes to deterioration, which can result in delisting or death while being on the waiting list.^{10,17–19} In ACHD, 1 year mortality after transplantation is high due to procedure related risk factors and advanced HF at the time of transplantation, but survival rates at 10 years are comparable or even better than those of patients with acquired heart disease.^{17–19} The reason for the better long-term survival is often attributed to the younger age at transplantation and the lower infection and malignancy rates following transplantation.¹⁹ In general, predictors of a poor outcome on the waiting list are comparable between ACHD and non-ACHD with the exception that previous cardiac surgery was more often related to a poor outcome in non-ACHD.¹⁰ In addition, non-ACHD have more established advanced HF therapies to extend the time on the waiting list such as VAD therapy or use of inotrope medication.¹⁰

The ARTORIA-R will collect data on a global scale to identify these factors and highlight the risks for ACHD with advanced HF evaluated or listed for heart transplantation. In addition, besides these general considerations, other important factors have to be considered as well in ACHD, these are the following.

Anatomic complexity/previous cardiac surgery

The most common problem complicating ACHD transplantation is related to the variability of the underlying cardiac anatomy and physiology.^{17,18} Although recent studies evaluate this in more detail,^{17,18} the management of these complex anatomic variants is still not fully established, and additional evidence is needed. Transplantation is complicated by scarring caused by previous surgery, collateral vessels, and bleeding issues.^{1,14,18} There is the need of more data regarding the exact anatomic diagnosis of the underlying heart defects, lacking in these recent studies^{17,18}, or only mentioned as a general congenital heart defect^{10,19}; thus, a register specifically obtaining this granular data will significantly contribute to this debate.

Ventricular assist devices

Due to organ shortage and the fact that the need for organ transplantation is increasing in both non-ACHD and ACHD,^{1,8} the use of VADs became a more established treatment option both for bridge to transplant and destination therapy.⁸ However, the use of VADs in ACHD is not straightforward as there are no clear recommendations for this cohort of patients. A recent large study suggested that ACHD may gain a benefit in terms of being able to wait longer for an organ transplantation before fatal deterioration occurs.²⁰ However, again patients were only described as ACHD without classification of

the underlying anatomical disease.²⁰ Due to the described heterogeneity of ACHD, more data are needed with a clear description of the underlying defect. Data from a recent study provided more details regarding the underlying anatomy of the ventricle needing support and showed that the survival of ACHD and non-ACHD was similar, but ACHD needing biventricular VAD had a poor outcome.²¹ Thus, the ARTORIA register as described could provide more background information on this important topic as VAD might be an option to stabilize ACHD and prolong the time on the waiting list comparable with non-ACHD.⁸

Device treatment and arrhythmia management

In ACHD, the entire spectrum of arrhythmias can be encountered where some are caused by advanced HF and some are due to the surgery for anatomical or palliative correction with scarring or a consequent remodelling of the heart.^{1,22,23} While some forms of arrhythmia are treatable,^{1,22,23} some types of arrhythmia worsen with advanced HF and indicate a poor prognosis emphasizing the need for urgent listing for organ transplantation.^{1,22,23} Recommendations which ACHD should receive an ICD while on the waiting list are less clear although a recent joint position paper provides a consensus opinion when ICD for ACHD on the waiting list may be considered.²² While its use is established in patients without congenital heart disease,^{24,25} its use is not generally comparable in ACHD due to the different anatomy and risk factors for implantation.^{22,23} The ARTORIA-R register includes variables detailing the use of ICD or CRT in ACHD in conjunction with antiarrhythmic medication and presence of previous events like atrial fibrillation ablation or ventricular tachycardia ablation. Thus, as pointed out in the current guidelines, study results will shed more light on characterizing ACHD and advanced HF. Again highlighting that more data on this topic are needed especially in the context of absence of randomized clinical trials in ACHD.

Co-morbidities, particularly pulmonary arterial hypertension

Co-morbidities are often present in ACHD listed for heart or heart/lung transplantation with PAH being very common.^{1,17,18,26} More data are needed to study how this co-morbidity affects the outcome of patients on the waiting list. Especially the most advanced form of PAH with Eisenmenger syndrome due to an uncorrected shunt lesion is reported to have a poor outcome.^{27,28} The timing when these patients should be evaluated or listed for organ transplantation is difficult, and there is the need to document organ function of the liver or renal function as well. Patients with too many co-morbidities with poor liver or renal function might not be candidates for

transplantation listing. However, specific medical treatment of patients on the waiting list and numbers regarding combined heart/lung transplantation and long-term outcome of these patients is still scarce. This fact underlines the need of more data regarding patients with advanced forms of PAH in ACHD or even Eisenmenger syndrome as the most severe form of PAH.

In summary, ARTORIA-R is one of the largest registries collecting data of ACHD with advanced HF evaluated for transplantation or listed for heart-only or heart-combined organ transplantation from multiple countries and regions. This register aims to improve treatment of patients by investigating prognostic factors and thus allow for a better risk stratification. Furthermore, the register aims to promote research and awareness for ACHD with advanced heart failure.

Acknowledgements

The authors thank the staff of all organizations contributing data to the register. Open access funding enabled and organized by Projekt DEAL.

Conflict of interest

Dr. Sinning (CS) is deputy editor of the *European Heart Journal – Case Reports*. Dr. Zengin (EZ) reports speaker fees from AstraZeneca unrelated to the submitted work. Dr. Magnussen (CM) reports speaker fees from AstraZeneca, Novartis, and Heinen & Loewenstein unrelated to the submitted work. Dr. Bernhardt (AB) reports speaker and consulting fees from Abbott, Abiomed, AstraZeneca, Berlin Heart, Medtronic, and Novartis unrelated to the submitted work. Dr. Schoenrath (FS) reports non-financial support from Medtronic, grants from Novartis and institutional fees from Cardiorentis AG, Abbott, AstraZeneca, and Orion Pharma unrelated to the submitted work. Dr. Ius (FI) has received speaker fees and congress fees from Biotest AG unrelated to the submitted work. Dr. Fabritz (LF) has received institutional research grants and non-financial support from European Union, British Heart Foundation, Medical Research Council (UK), several biomedical companies and DFG. The Institute of Cardiovascular Research, University of Birmingham, has received an Accelerator Award by the British Heart Foundation AA/18/2/34218. LF is listed as inventor of two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Dr. Kirchhof (PK) receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council

(UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last 3 years. PK is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). All other authors have no conflicts of interest in relation to the content of this manuscript.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Data S1. Supporting information.

Data S2. Supporting information.

Data S3. Supporting information.

References

- Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, Lung B, Kluin J, Lang IM, Meijboom F, Moons P, Mulder BJM, Oechslin E, Roos-Hesselink JW, Schwerzmann M, Sondergaard L, Zeppenfeld K, Group ESCSD. 2020 ESC Guidelines for the management of adult congenital heart disease. *Eur Heart J* 2021; **42**: 563–645.
- Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. *Circulation* 2007; **115**: 163–172.
- Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. *Circulation* 2014; **130**: 749–756.
- Kaemmerer H, Bauer U, Pensl U, Oechslin E, Gravenhorst V, Franke A, Hager A, Balling G, Hauser M, Eicken A, Hess J. Management of emergencies in adults with congenital cardiac disease. *Am J Cardiol* 2008; **101**: 521–525.
- Khairy P, Ionescu-Ittu R, Mackie AS, Abrahamowicz M, Pilote L, Marelli AJ. Changing mortality in congenital heart disease. *J Am Coll Cardiol* 2010; **56**: 1149–1157.
- Verheugt CL, Uiterwaal CS, van der Velde ET, Meijboom FJ, Pieper PG, van Dijk AP, Vliegen HW, Grobbee DE, Mulder BJ. Mortality in adult congenital heart disease. *Eur Heart J* 2010; **31**: 1220–1229.
- Stout KK, Broberg CS, Book WM, Cecchin F, Chen JM, Dimopoulos K, Everitt MD, Gatzoulis M, Harris L, Hsu DT, Kuvin JT, Law Y, Martin CM, Murphy AM, Ross HJ, Singh G, Spray TL, American Heart Association Council on Clinical Cardiology CoFG, Translational B, Council on Cardiovascular R, Imaging. Chronic heart failure in congenital heart disease: a scientific statement from the American heart association. *Circulation* 2016; **133**: 770–801.
- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016; **18**: 891–975.
- Budts W, Roos-Hesselink J, Radle-Hurst T, Eicken A, McDonagh TA, Lambrinou E, Crespo-Leiro MG, Walker F, Frogoudaki AA. Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology. *Eur Heart J* 2016; **37**: 1419–1427.
- Alshawabkeh LI, Hu N, Carter KD, Opatowsky AR, Light-McGroary K, Cavanaugh JE, Bartlett HL. Wait-list outcomes for adults with congenital heart disease listed for heart transplantation in the U.S. *J Am Coll Cardiol* 2016; **68**: 908–917.
- Gandjibakhch E, Redheuil A, Pousset F, Charron P, Frank R. Clinical diagnosis, imaging, and genetics of arrhythmogenic right ventricular cardiomyopathy/dysplasia: JACC state-of-the-art review. *J Am Coll Cardiol* 2018; **72**: 784–804.
- Sedaghat-Hamedani F, Haas J, Zhu F, Geier C, Kayvanpour E, Liss M, Lai A, Frese K, Pribe-Wolferts R, Amr A, Li DT, Samani OS, Carstensen A, Bordalo DM, Muller M, Fischer C, Shao J, Wang J, Nie M, Yuan L, Hassfeld S, Schwartz C, Zhou M, Zhou Z, Shu Y, Wang M, Huang K, Zeng Q, Cheng L, Fehlmann T, Ehlermann P, Keller A, Dieterich C, Streckfuss-Bomeke K, Liao Y, Gotthardt M, Katus HA, Meder B. Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy. *Eur Heart J* 2017; **38**: 3449–3460.
- Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. *Stat Med* 2017; **36**: 4391–4400.
- Nguyen VP, Dolgner SJ, Dardas TF, Verrier ED, McMullan DM, Krieger EV. Improved outcomes of heart transplantation in adults with congenital heart disease receiving regionalized care. *J Am Coll Cardiol* 2019; **74**: 2908–2918.
- Cordina R, Nasir Ahmad S, Kotchetkova I, Eveborn G, Pressley L, Ayer J, Chard R, Tanous D, Robinson P, Kilian J, Deanfield JE, Celermajer DS. Management errors in adults with congenital heart disease: prevalence, sources, and consequences. *Eur Heart J* 2018; **39**: 982–989.
- Lo Rito M, Poretti G, Varrica A, Negura D, Micheletti A, Chessa M, Giamberti A. The challenging pathway toward heart transplant listing for adult congenital heart disease patients. *Artif Organs* 2018; **42**: 911–917.
- Becher PM, Schrage B, Weimann J, Smits J, Magnussen C, Reichensperner H, Gossling A, Rodrigus I, Dumfarth J, de Pauw M, Francois K, van Caenegem O, Ancion A, Van Cleemput J, Milicic D, Moza A, Schenker P, Rohrich L, Schonrath F, Thul J, Steinmetz M, Schmack B, Ruhparwar A, Warnecke G, Rojas SV, Sandhaus T, Haneya A, Eifert S, Welp H, Ablonczy L, Wagner F, Westermann D, Bernhardt AM, Knappe D, Blankenberg S, Kirchhof P, Zengin E, Sinning C. Clinical characteristics and outcomes of patients with adult congenital heart disease listed for heart and heartlung transplantation in the Eurotransplant region. *J Heart Lung Transplant* 2020; **39**: 1238–1249.
- Crossland DS, Jansen K, Parry G, Harper A, Perri G, Davidson A, De Rita F, Hermuzi A, Nassar M, Seller N, MacGowan GA, Hasan A, O'Sullivan JJ, Coats L. Outcome following heart transplant assessment in adults with congenital heart disease. *Heart* 2019; **105**: 1741–1747.
- Burchill LJ, Edwards LB, Dipchand AI, Stehlik J, Ross HJ. Impact of adult congenital heart disease on survival and mortality after heart transplantation. *J*

- Heart Lung Transplant* 2014; **33**: 1157–1163.
20. Cedars A, Tecson KM, Zaidi AN, Lorts A, McCullough PA. Impact of durable ventricular assist device support on outcomes of patients with congenital heart disease waiting for heart transplant. *ASAIO J* 2020; **66**: 513–519.
 21. VanderPluym CJ, Cedars A, Eghtesady P, Maxwell BG, Gelow JM, Burchill LJ, Maltais S, Koehl DA, Cantor RS, Blume ED. Outcomes following implantation of mechanical circulatory support in adults with congenital heart disease: an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). *J Heart Lung Transplant* 2018; **37**: 89–99.
 22. Hernandez-Madrid A, Paul T, Abrams D, Aziz PF, Blom NA, Chen J, Chessa M, Combes N, Dagres N, Diller G, Ernst S, Giamberti A, Hebe J, Janousek J, Kriebel T, Molledo J, Moreno J, Peinado R, Pison L, Rosenthal E, Skinner JR, Zeppenfeld K, Group ESCSD. Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE. *Eurpace* 2018; **20**: 1719–1753.
 23. Khairy P, Van Hare GF, Balaji S, Berul CI, Cecchin F, Cohen MI, Daniels CJ, Deal BJ, Dearani JA, Groot N, Dubin AM, Harris L, Janousek J, Kanter RJ, Karpawich PP, Perry JC, Seslar SP, Shah MJ, Silka MJ, Triedman JK, Walsh EP, Warnes CA. PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). *Heart Rhythm* 2014; **11**: e102–65.
 24. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J* 2015; **36**: 2793–2867.
 25. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, Guidelines ESCCfP, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendra M, Torbicki A, Wijns W, Windecker S, Document R, Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bansch D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu D, Faerstrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tendra M, Van Gelder IC, Wilson CM. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *Eur Heart J* 2013; **34**: 2281–2329.
 26. Menachem JN, Schlenker KH, Mazurek JA, Bichell DP, Brinkley DM, Frischhertz BP, Mettler BA, Shah AS, Zalawadiya S, Book W, Lindenfeld J. advanced heart failure in adults with congenital heart disease. *JACC Heart Fail* 2020; **8**: 87–99.
 27. Hjortshoj CMS, Kempny A, Jensen AS, Sorensen K, Nagy E, Dellborg M, Johansson B, Rudiene V, Hong G, Opatowsky AR, Budts W, Mulder BJ, Tomkiewicz-Pajak L, D'Alto M, Prokselj K, Diller GP, Dimopoulos K, Estensen ME, Holmstrom H, Turanlahti M, Thilen U, Gatzoulis MA, Sondergaard L. Past and current cause-specific mortality in Eisenmenger syndrome. *Eur Heart J* 2017; **38**: 2060–2067.
 28. Diller GP, Korten MA, Bauer UM, Miera O, Tutarel O, Kaemmerer H, Berger F, Baumgartner H. German Competence Network for Congenital Heart Defects I. Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects. *Eur Heart J* 2016; **37**: 1449–1455.